Clinical Trial Update: Safety of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke [Phase 2]

View source ↗

Summary

Phase 2 safety update on NXY-059 in patients who have suffered an intracerebral hemorrhage after stroke. The trial status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Intracerebral Hemorrhage

Drugs mentioned

• NXY-059 (NXY-059)

Snippet

Sponsor: AstraZeneca | Conditions: Intracerebral Hemorrhage | Phase 2 | Status: COMPLETED